title: The office management of recalcitrant rhinosinusitis.
abstract: The patient referred to the otolaryngologist for the treatment of CRS has received many therapies for the condition. Newer therapies available focus on the anti-inflammatory therapies and local application of antimicrobial and antifungal agents to the sinus cavities. Much clinical work remains to be done to prove the efficacy of currently available treatments. The recent advances in the understanding of allergic and immune mechanisms may allow eventual intervention at the level of cytokines and other immunomodulators of inflammation. The complex cascade of interleukins and proinflammatory agents in CRS patients may some day allow "silver bullet" therapies in the properly selected patient. Until then, a systematic approach to the evaluation of these patients and management with the currently available treatment modalities may help relieve the symptoms in patients with CRS.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Zacharek
authors.forename: Peter H
authors.initials: PH
authors.lastname: Hwang
authors.forename: Karen J
authors.initials: KJ
authors.lastname: Fong
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D006801:Humans; D012852:Sinusitis / Q000145:classification* / Q000188:drug therapy* / Q000235:genetics
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents